Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Key Record Dates Identifier: NCT01754870
Brief Title: Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

First Submitted : November 27, 2012
First Submitted that Met QC Criteria : December 18, 2012
First Posted : December 21, 2012 (Estimate)

Last Update Submitted that Met QC Criteria : November 13, 2019
Last Update Posted : November 15, 2019